Drug Database
CO

COVID-19 vaccine (S 268019 / S268019 / Covgoze)

✓ Approved

Shionogi · Recombinant Proteins · Recombinant Proteins

What is COVID-19 vaccine?

COVID-19 vaccine is a recombinant proteins developed by Shionogi. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesS 268019, S268019, Covgoze
CompanyShionogi
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Shionogi

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedHuman vaccines & immunotherapeutics2026-08-25

How the unvaccinated have been portrayed in the urban English-language Canadian popular press since the declared end of the COVID-19 pandemic emergency.

Marcon Alessandro R AR, Boniface Vincenza V, Caulfield Timothy T

Since the WHO declared the end of the COVID-19 emergency in May 2023, public vaccination remains a complex issue intertwined with politicization and misinformation. This research article examined how the "unvaccinated" have been portrayed in the urban English-language Canadian popular press between May 2023 and May 2025, specifically comparing coverage of COVID-19 with the emerging 2024-2025 measles outbreaks. Through a content analysis of 308 articles from major national and urban news sources, the study reveals a dichotomy in journalistic framing. Findings indicate that COVID-19 reporting remained heavily politicized and rooted in ideological debates. These articles focused primarily on politics, mandate arguments, government critiques, and claims of discrimination against the unvaccinated, with only 40% mentioning unvaccinated health risks to oneself or others. In contrast, measles coverage adopted a more traditional public health lens; 96% of these articles characterized being unvaccinated as a health risk to oneself or others, frequently emphasizing vaccine importance and uptake strategies while largely avoiding broader socio-political issues. The study suggests that while the Canadian popular press successfully conveys scientific urgency in novel or acute health threats like measles, its continued focus on socio-political conflict regarding COVID-19 represents problematic science communication. Covering "agenda-setting" political narratives is an important aspect of the COVID-19 pandemic but should not dominate or stand in place of evolving clinical evidence on reinfection and vaccine efficacy. Depoliticizing scientific realities and reintegrating established health-risk data into all vaccine-related reporting is necessary for supporting public health in any infectious disease contexts.

PMID 42638279
Read full article →
PubMedOpen forum infectious diseases2026-08-25

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains.

Holmes Anna A, Narayan Kristin K, Yalcin Ilker I, Hu Leijun L et al.

Multiple SARS-CoV-2 receptor-binding domain-directed monoclonal antibodies (mAbs) have demonstrated substantial efficacy for the treatment of COVID-19. However, rapid virus evolution challenges traditional development pathways, as nonsusceptible variants can outpace development and regulatory review. Fortunately, mAb antiviral activity across variants can be measured via clinical serum virus-neutralizing antibody titers that correlate to clinical outcomes from historical mAbs and serve as surrogate biomarkers for efficacy. Analytic immunobridging facilitates rapid assessment of novel mAb efficacy. Immunobridging supported the Emergency Use Authorization of pemivibart, a mAb targeted to the spike protein of SARS-CoV-2 for the prevention of COVID-19 in certain patients with immune compromise. We applied a similar framework to evaluate pemivibart for the treatment of acute COVID-19. Complementary methods included the following: (1) strict immunobridging of neutralizing antibody titers of pemivibart to its parent molecule adintrevimab, (2) benchmarking comparison of pemivibart to historical mAbs with demonstrated efficacy in COVID-19 treatment, and (3) dose-response analysis of pemivibart vs comparator mAbs based on a meta-analysis. Pemivibart demonstrated strict immunobridging to adintrevimab from 4 to >14 days across the variants analyzed. Neutralizing titers of pemivibart were 4- to 12-fold higher than titers for sotrovimab and less than titers for other historical intravenously administered mAbs throughout a 14-day analysis period. Dose-response analysis predicted pemivibart to have equivalent efficacy to all comparators. Following a similar approach to prevention, immunobridging was demonstrated for pemivibart for the treatment of COVID-19, suggesting substantial antiviral activity. This development methodology provides a roadmap for accelerating novel COVID-19 treatment options amid a changing variant landscape.

PMID 42639460
Read full article →
PubMedIrish medical journal2026-08-25

Experience of Systematic Deficits in Healthcare During SARS-CoV-2: A Rapid-Response Survey of Healthcare Assistants.

Conyard K F KF, Metcalfe A A, McAllister N N, Jalili P P et al.

To describe Irish Healthcare Assistants'/carers' (HCAs) working conditions and wellbeing during COVID-19 Wave 1 and examine associations between PPE access and infection-related outcomes. A 24-hour rapid-response, mixed-method survey (23/04/2020) of HCAs/carers in Ireland (456) across care settings. Quantitative data (sector/setting, PPE, training, redeployment, pay, sick leave/isolation) were analysed in SPSS; free-text responses underwent thematic analysis (manual and N-Vivo12). Full PPE followed the HSE HPSC definition. Most respondents worked in the private sector (255, 56%) and in community/homecare (201, 44%). PPE access was variable: unlimited (104, 22.8%), limited (96, 21.0%), reasonable (105, 23.0%), and none (14, 3.1%). COVID-19 sick leave/isolation was reported at 80 (17.5%). Minimal COVID-19 training was reported at 173 (38%) and supportive management at 150 (33%). Movement between locations occurred in 167(36.6%); 252 respondents would decline nursing-home redeployment even with incentives. Full PPE access was associated with lower COVID-19 positivity (2.6%, p=0.031) and fewer close-contact identifications (0.9% vs 9.4%, p=0.022). Qualitative themes emphasised fear of infection, anxiety about transmitting COVID-19 to family, and poor real-time guidance. Wave 1 exposed persistent gaps in PPE, training, leadership communication, and support for HCAs. Standardised PPE access, consistent IPC training, improved managerial communication, mental health supports, and stronger regulation/professional recognition remain priorities.

PMID 42640271
Read full article →
PubMedJournal of Nepal Health Research Council2026-08-25

Association of Laboratory Parameters with Clinical Outcomes of SARS-CoV-2 Patients.

Sharma Neupane Mamata M, Hassan Hafizah Che HC, Uranw Surendra Kumar SK, Mehta Raj Kumar RK

The COVID-19 pandemic has imposed a significant burden on healthcare systems, particularly in resource-limited settings. Laboratory biomarkers may help predict disease outcomes and guide clinical decisions. However, there is limited evidence from Nepal regarding the prognostic value of these markers among hospitalized COVID-19 patients. A hospital-based observational study was conducted among 348 RT-PCR-confirmed COVID-19 patients admitted to the COVID ICUs and wards of a tertiary care hospital in Nepal between March 2022 and June 2023. Data on sociodemographic characteristics, haematological parameters, liver and inflammatory markers, urine microscopy, and SARS-CoV-2 molecular gene markers were collected prospectively. Clinical outcomes were categorized as survived or died. Descriptive statistics, chi-square tests, and binary logistic regression were used to analyse associations and identify predictors of mortality. Out of the total 348 patients included in the study, 71 patients (20.4%) died, while 277 patients (79.6%) survived. Among 348 patients, significant associations with mortality were observed for lymphopenia (p = .001), neutrophilia (p < .001), elevated ALT (p < .001), elevated AST (p = .001), and positive D-dimer (p < .001). High viral load (Ct value ?20) for E, N, and ORF1ab ab genes was also significantly associated with mortality in univariate analysis. Logistic regression identified D-dimer positivity (OR = 0.027, p = .001) and elevated ALT (OR = 0.356, p = .016) as independent predictors of mortality. Laboratory parameters, especially lymphocyte count, D-dimer, and ALT levels, are valuable prognostic indicators of clinical outcomes in hospitalized COVID-19 patients. Integrating these markers into clinical assessment may enhance early risk stratification and resource allocation.

PMID 42638237
Read full article →
PubMedERJ open research2026-08-25

Rethinking treatment approaches to organising pneumonia: more lessons to be learned from COVID-19.

Allison Margaret B MB, Montesi Sydney B SB

In this issue of ERJ Open Research, Espejo-Castellanoset al. present a noninferiority trial comparing two dosage regimens of prednisone for post-COVID organising pneumonia (OP) providing important insight into treatment duration of secondary OP https://bit.ly/422MWzj.

PMID 42639056
Read full article →
PubMedHolistic nursing practice2026-08-25

The Effects of Aromatherapy With Thyme Oil on Disease Symptoms, Vital Findings, and Hemodynamic Parameters in COVID-19 Patients: Erratum.

Öner Uğur U, Cengiz Zeliha Z, Erol Ahmet A

PMID 42638338
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine